Published in Otolaryngol Head Neck Surg on November 01, 1990
A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci U S A (1992) 2.76
Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc Natl Acad Sci U S A (1991) 2.17
Xenograft models of head and neck cancers. Head Neck Oncol (2009) 1.37
Diffusion magnetic resonance imaging: an imaging treatment response biomarker to chemoradiotherapy in a mouse model of squamous cell cancer of the head and neck. Transl Oncol (2008) 1.09
Animal models of cancer in the head and neck region. Clin Exp Otorhinolaryngol (2009) 0.95
Hypoxia-induced autophagic response is associated with aggressive phenotype and elevated incidence of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell carcinomas (HNSCC). Exp Mol Pathol (2011) 0.83
Immunotherapy in new pre-clinical models of HPV-associated oral cancers. Hum Vaccin Immunother (2013) 0.80
Reviewing and reconsidering invasion assays in head and neck cancer. Oral Oncol (2014) 0.80
Immunocompromised and immunocompetent mouse models for head and neck squamous cell carcinoma. Onco Targets Ther (2016) 0.79
New orthotopic implantation model of human esophageal squamous cell carcinoma in athymic nude mice. Thorac Cancer (2014) 0.77
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol (1997) 29.02
Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med (1979) 6.00
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol (1996) 4.07
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med (1997) 3.64
Quantitative analysis of MDR1 (multidrug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci U S A (1990) 3.03
Diet in the epidemiology of postmenopausal breast cancer in the New York State Cohort. Am J Epidemiol (1992) 2.17
Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. J Clin Oncol (1999) 2.00
Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep (1980) 1.99
Pulmonary edema as a complication of acute airway obstruction. JAMA (1977) 1.96
Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med (1981) 1.92
In vivo measures of cochlear length and insertion depth of nucleus cochlear implant electrode arrays. Ann Otol Rhinol Laryngol Suppl (1998) 1.87
Double minute chromosomes can be produced from precursors derived from a chromosomal deletion. Mol Cell Biol (1988) 1.81
G-quadruplexes as targets for drug design. Pharmacol Ther (2000) 1.63
Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res (1999) 1.63
A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res (2000) 1.59
Characterization of an episome produced in hamster cells that amplify a transfected CAD gene at high frequency: functional evidence for a mammalian replication origin. Mol Cell Biol (1987) 1.58
Transforming growth factor beta: potential autocrine growth inhibitor of estrogen receptor-negative human breast cancer cells. Cancer Res (1988) 1.57
Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J Clin Oncol (2000) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) Clin Cancer Res (1999) 1.54
Intensity-modulated radiation therapy reduces late salivary toxicity without compromising tumor control in patients with oropharyngeal carcinoma: a comparison with conventional techniques. Radiother Oncol (2001) 1.51
Diagnostic reliability of needle biopsy of the parietal pleura. A review of 272 biopsies. Am J Clin Pathol (1975) 1.48
Prospective clinical trial of a human tumor cloning system. Cancer Res (1983) 1.44
Meta-analysis of second malignant tumors in head and neck cancer: the case for an endoscopic screening protocol. Ann Otol Rhinol Laryngol (1992) 1.43
A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Ann Oncol (1996) 1.43
Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med (1977) 1.42
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma. Cancer (1999) 1.41
Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol (1996) 1.41
A method for the evaluation of dose-toxicity relationships in clinical trials. Stat Med (1989) 1.39
Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo. J Natl Cancer Inst (1990) 1.38
Clinical correlates of MDR1 (P-glycoprotein) gene expression in ovarian and small-cell lung carcinomas. J Natl Cancer Inst (1992) 1.33
A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol (1999) 1.32
Spouse-subject interviews and the reliability of diet studies. Am J Epidemiol (1980) 1.26
Pseudomonas mastoiditis. Laryngoscope (1977) 1.24
Predictive value of tympanometry in middle ear effusion. Ann Otol Rhinol Laryngol (1986) 1.22
Diet in the epidemiology of carcinoma of the prostate gland. J Natl Cancer Inst (1983) 1.22
'Appropriateness' of tympanostomy tubes. Setting the record straight. Arch Otolaryngol Head Neck Surg (1994) 1.21
Hearing loss and antiretroviral therapy in patients infected with HIV-1. Arch Neurol (1997) 1.21
Maggot therapy for subacute mastoiditis. Arch Otolaryngol (1976) 1.21
Infusions of recombinant human interleukins 1 alpha and 1 beta cause hypercalcemia in normal mice. Proc Natl Acad Sci U S A (1988) 1.20
Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol (1995) 1.20
Taxol: a new and effective anti-cancer drug. Anticancer Drugs (1991) 1.17
Esthesioneuroblastoma: the impact of treatment modality. Head Neck (2001) 1.17
"Send this patient's tumor for culture and sensitivity". N Engl J Med (1983) 1.17
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst (1992) 1.16
The cardiotoxicity of anticancer agents. Semin Oncol (1982) 1.15
cis-Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer. Cancer Treat Rep (1980) 1.15
Workshop on effects of otitis media on the child. Pediatrics (1983) 1.15
Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days. Eur J Cancer (1994) 1.15
Masked mastoiditis. Laryngoscope (1983) 1.15
In vitro stem cell assay in head and neck squamous carcinoma. Am J Surg (1980) 1.14
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol (1998) 1.14
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Functional MR spectroscopy of the auditory cortex in healthy subjects and patients with sudden hearing loss. AJNR Am J Neuroradiol (1997) 1.12
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer (2012) 1.11
Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs (1991) 1.11
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol (1999) 1.11
Telomere-interactive agents affect proliferation rates and induce chromosomal destabilization in sea urchin embryos. Anticancer Drug Des (1999) 1.11
Human tumor cloning: feasibility and clinical correlations. Cancer Chemother Pharmacol (1981) 1.10
An inquiry into the epidemiology of melanoma. Am J Epidemiol (1985) 1.10
5-Azacytidine. A new anticancer drug with effectiveness in acute myelogenous leukemia. Ann Intern Med (1976) 1.10
Medical treatment of chronic otitis media with effusion (secretory otitis media). Otolaryngol Head Neck Surg (1986) 1.09
Measure once or twice -- does it really matter? J Natl Cancer Inst (1999) 1.09
Mitoxantrone in epithelial carcinoma of the ovary. A Southwest Oncology Group study. Am J Clin Oncol (1984) 1.08
Measuring the indirect and direct costs of acute otitis media. Arch Otolaryngol Head Neck Surg (1999) 1.08
Determination of the position of nucleus cochlear implant electrodes in the inner ear. Am J Otol (1994) 1.07
Investigation of taxol as a potential radiation sensitizer. Cancer (1993) 1.05
Mitoxantrone: a new anticancer drug with significant clinical activity. Ann Intern Med (1986) 1.04
Diet in the epidemiology of gastric cancer. Nutr Cancer (1990) 1.04
Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP. J Clin Oncol (1998) 1.04
Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration. Cancer Treat Rep (1977) 1.04
Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units. Anticancer Drugs (1998) 1.04
Manometry of the normal upper esophageal sphincter and its alterations in laryngectomy. J Clin Invest (1979) 1.03
CC-1065 (NSC 298223), a most potent antitumor agent: kinetics of inhibition of growth, DNA synthesis, and cell survival. Cancer Res (1982) 1.03
Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res (1991) 1.03
Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep (1986) 1.03
Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res (1987) 1.03
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol (1999) 1.02
Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S. Cancer Res (1997) 1.02
Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. J Natl Cancer Inst (1994) 1.02
Primary adrenal lymphoma. Cancer (1989) 1.02
Use of an image analysis system to count colonies in stem cell assays of human tumors. Prog Clin Biol Res (1980) 1.02
A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days. Anticancer Drugs (1992) 1.01
Controversies in screening for middle ear disease and hearing loss in children. Pediatrics (1986) 1.01
Measuring quality of life in children with obstructive sleep disorders. Arch Otolaryngol Head Neck Surg (2000) 1.00
Regulation of catalytic activity and processivity of human telomerase. Biochemistry (1999) 1.00
Design and synthesis of fluoroquinophenoxazines that interact with human telomeric G-quadruplexes and their biological effects. Mol Cancer Ther (2001) 1.00
Sialography and scanning of the salivary glands. Otolaryngol Clin North Am (1977) 0.99
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci U S A (1994) 0.98
Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies. J Clin Oncol (1986) 0.98
An abbreviated impedance bridge technique for school screening. J Speech Hear Disord (1975) 0.98
Telomerase assay using biotinylated-primer extension and magnetic separation of the products. Biotechniques (1998) 0.98
Adjuvant hyperbaric oxygen in malignant external otitis. Arch Otolaryngol Head Neck Surg (1992) 0.97
Noise-induced hearing loss in young adults: the role of personal listening devices and other sources of leisure noise. Laryngoscope (1998) 0.97
Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors. Ann Oncol (1998) 0.97
Unilateral tonsillar enlargement. Otolaryngol Head Neck Surg (1979) (1980) 0.97
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res (1999) 0.97
Improved plating efficiencies for human tumors cloned in capillary tubes versus Petri dishes. Cancer Res (1986) 0.97